Similar Articles
111 Rifaximin-α use is associated with improved muscle mass in patients with cirrhosis
112 Multidisciplinary tumor board is associated with improved survival in patients with hepatocellular carcinoma after liver transplantation
113 Pretreatment radiomic imaging features combined with immunological indicators to predict targeted combination immunotherapy response in advanced hepatocellular carcinoma
114 Long non-coding RNA in the regulation of cell death in hepatocellular carcinoma
115 Current status and recent progress of nanomaterials in transcatheter arterial chemoembolization therapy for hepatocellular carcinoma
116 Management of hepatic encephalopathy following transjugular intrahepatic portosystemic shunts: Current strategies and future directions
117 Rethinking carnitine palmitoyltransferase II and liver stem cells in metabolic dysfunction-associated fatty liver disease-related hepatocellular carcinoma
118 Multi-omics reveals the associations among the fecal metabolome, intestinal bacteria, and serum indicators in patients with hepatocellular carcinoma
119 Immune checkpoint inhibitors plus anti-angiogenesis in patients with resected high-risk hepatitis B virus-associated hepatocellular carcinoma
120 Hepatocellular carcinoma resistance to tyrosine kinase inhibitors: Current status and perspectives
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA